FindTrial
Sign In

Concurrent Chemoradiotherapy Followed by Surgical Resection for Stage III Thymoma or Thymic Carcinoma

Phase II Study of Concurrent Chemoradiotherapy Followed by Surgical Resection for Stage III Thymoma or Thymic Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-TNC-10001204
Enrollment
Unknown
Registered
2010-10-20
Start date
2008-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thymoma or Thymic Carcinoma

Interventions

1:Drug: docetaxol: 60mg/m^2, d1
cisplatin: 35mg/m^2, d1, d2, administered every 28 days. Radiation: 3-D conformal radiotherapy or IMRT radiotherapy, total dose: 40Gy.

Sponsors

Shanghai Chest Hospital,
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Bpopsy-proven thymoma or thymic carcinoma; 2. Stage III thymic tumor determined by CT scan or other images; 3. Acceptable heart, liver, kidney and respiratory functions.

Exclusion criteria

Exclusion criteria: 1. Radiographic evidence of stage IV thymoma; 2. Unable to tolerate surgical resection

Design outcomes

Primary

MeasureTime frame
Rate of complete resection;—

Secondary

MeasureTime frame
Long time survival;Pathological complete response;—

Countries

China

Contacts

Public ContactChanglu Wang
luise2w@msn.com+8613817125147

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026